KPV: research

KPV dosage

Typical reported dose: 150–300 mcg a day by mouth

• Oral pills, 150-300 mcg: 150-300 mcg per day reported; 600 mcg/day was only planned. daily; precise timing not reported, by mouth. Reported by users, occasional report. Studied in: Adults describing gut symptoms on a forum. (source)
• Reported 500 mcg daily: 500 mcg under the skin once daily. once daily, under the skin. Reported by users, occasional report. Studied in: One adult reporting gut-inflammation self-use. (source)
• Reported two-week steps: 250 mcg daily for 2 weeks., then 500 mcg daily for 2 weeks., then 1,000 mcg daily for 2 weeks. daily, as reported in the same discussion, under the skin. Reported by users, rare report. Studied in: One forum user describing use for MCAS-like symptoms. (source)
• Reported twice daily with BPC-157: 250 mcg KPV per injection, twice daily; also 250 mcg BPC-157 each time. twice daily, morning and evening, under the skin. Reported by users, rare report. Studied in: A secondhand report about an adult with SIBO symptoms. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

KPV side effects and risks

Reported side effects

• Human adverse-effect rates are unknown: No human safety trial or formal rate estimate. No reports in FDA searches through December 3, 2025 does not prove safety., moderate. Review new symptoms promptly; absence of reports is not evidence of safety. (source)
• Fatigue or symptom flares reported online: Unverified reports; no denominator or confirmed cause., moderate. Stop and seek assessment for worsening symptoms. (source)
• Possible serious allergic reaction: FDA describes immune reaction risk; KPV specific incidence is unknown., serious. Breathing trouble, throat swelling or fainting needs emergency care. (source)

Stop and get help if

• Trouble breathing, throat swelling or collapse: Stop exposure and get emergency help immediately.
• Fever with a spreading hot, painful injection site: Seek urgent care for possible infection.
• New severe or worsening symptoms after use: Stop and obtain medical assessment; do not assume a normal detox reaction.
• Severe belly pain, heavy or nonstop rectal bleeding, or vomiting blood: Get emergency medical help now.
• Bloody diarrhea with fever or a fast heartbeat: Obtain urgent same-day assessment; a severe bowel flare may need hospital care.

Who should avoid it

• pregnant: Precautionary block. No human pregnancy safety studies were found.
• breastfeeding: Precautionary block. Milk transfer and infant effects are unknown.
• tryingToConceive: Precautionary block. Reproductive and developmental safety is unstudied.
• under18: No pediatric dose or safety evidence; adult-only reference.
• melanomaOrAtypicalMoles: Melanoma safety is unstudied. KPV lacks alpha-MSH pigment activity in preclinical work; melanotan risks cannot simply be assigned to KPV.
• kidneyDisease: No human clearance or dose-adjustment data in kidney disease.
• liverDisease: No human clearance or dose-adjustment data in liver disease.
• immunosuppressed: Immune effects and infection risk with immunosuppressive treatment have not been tested in people.
• other: Avoid re-exposure after a suspected serious allergy to KPV or any ingredient.
• testedAthlete: S0 prohibits unapproved pharmacological substances at all times. Verify status with the relevant anti-doping body.

Interactions

• Systemic immunosuppressants: Precaution only. No human interaction data establish how KPV combines with immune-suppressing medicines.

Product quality risks

• FDA found inconsistent KPV naming and incomplete quality data, including missing microbiological tests.
• Unregulated peptides may have the wrong ingredient or amount, microbes, endotoxins, solvents or other contaminants.
• No independent market survey measuring contamination or underdosing of KPV products was found.

How KPV works

KPV can enter gut and immune cells through a small-peptide transporter called PepT1. In laboratory work it turns down some inflammation signals. It is a fragment of alpha-MSH, but its effects do not require the same pigment-making signal.

• PepT1 / SLC15A1: Carries KPV into gut and immune cells in laboratory experiments.
• NF-kappaB and MAPK: KPV reduced these inflammation signals in cells.
• MC1R: Mouse anti-inflammatory effects were partly independent of this pigment-related receptor.

Half-life: Unknown in humans; no published human pharmacokinetic study was found.